Breaks Categories: Stock Spotlights

FridayNov 03, 2017 12:14 pm

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Targets Global Cannabis Market

As a licensed producer under the Marijuana for Medical Purposes Regulations in Canada, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) sells cannabis through its ABcann Medicinals, Inc. subsidiary. “We’re now, hopefully, going to be a global presence,” director Aaron Keay said in an interview with CannabisFN (CFN Media). An article discussing this reads: “ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America (http://cnw.fm/3uiqM). The company sells in…

Continue Reading

ThursdayOct 12, 2017 9:30 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is Frontrunner in the Delivery of Non-Psychoactive Cannabinoids

Lexaria Biosciences Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has enhanced the ability of cannabinoid-products companies to deliver active ingredients to the body with its patent-protected technology. This technology is already being applied to the use of non-psychoactive cannabinoids, yielding a high-absorption hemp oil formula that is a source of omega and fatty acids, and patents are pending for tetrahydrocannabinol (THC) and other psychoactive cannabinoids along with nicotine and nonsteroidal anti-inflammatory drugs. An article discussing this reads: “The patent awarded to LXRP for the delivery of all non-psychoactive…

Continue Reading

WednesdayOct 11, 2017 2:35 pm

CannabisNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Sharpens Focus on Potentially Game-Changing Sustained Release Cannabinoid Formulation

Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) recently entered into a collaboration and licensing agreement with Canntab Therapeutics Limited to collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of Canntab’s patent-pending oral sustained release cannabinoid formulation. The agreement grants Emblem the exclusive right to Canntab’s patents and expertise in Canada to develop, commercialize, use, sell and offer—but not import or export—the product, which will be sold under the Emblem brand. An article discussing this reads: “For pharmaceutical ingredients that are typically short-acting, like cannabinoids, sustained release formulations enable dosage schedules that are…

Continue Reading

WednesdayOct 11, 2017 2:34 pm

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Scales Up in Preparation for Canada’s Impending 2018 Recreational Cannabis Legalization

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) was one of the first companies to obtain a cannabis production license in Canada, and it continues going strong among the country’s limited number of licensed growers—only 62 to date. The company’s high-tech indoor growing environment—with every facet of the growing, curing and harvesting process controlled and monitored by computer—yields a high-quality product that is clean, steady and repeatable—something the company can effectively leverage should recreational cannabis legalization go through in 2018. An article discussing this reads: “Focused on scaling its operations and distinguishing itself through its proprietary organic and pesticide-free growing technology,…

Continue Reading

TuesdayOct 03, 2017 1:23 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Breakthrough Lipid-Based Delivery System Revolutionizes Delivery of Cannabinoids and More

Pioneering biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed a breakthrough lipid-based system that facilitates more efficient delivery of bioactive compounds—not only enhancing bio-absorption and bioavailability but also improving taste, smell and the onset of action. Lexaria intends to out-license this patented and proprietary technology, and the company has already applied this delivery technology to its line of products, which includes ViPova, Lexaria Energy and TurboCBD. An article further discussing this reads: “Lexaria’s novel technology, DehydraTECH™, ticks all these boxes by infusing the molecules of organically sourced hemp oil, high in cannabidiol (CBD), inside the molecules of…

Continue Reading

FridaySep 29, 2017 3:01 pm

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Achieves $43M in Working Capital, Eyes Substantial Production Capacity Increase for 2018

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), a manufacturer and distributor of medical cannabis in Canada, announced on August 29 (http://cnw.fm/X6GSl) the achievement of working capital in the amount of $43 million from multiple financings, including strategic partnerships and private placements, during the six months ended June 30, 2017. During that period, ABcann recorded revenues of C$264,319, compared with $21,465 during the same period of 2016. For the six-month period ended June 30, the company’s revenues were $436,802, as compared with $21,840 for comparable period of the previous year. An article further discussing this reads: “ABcann’s first quarter as a…

Continue Reading

FridaySep 15, 2017 1:58 pm

CannabisNewsBreaks – University of British Columbia to Conduct Clinical Study of Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Game-Changing Oral CBD Product

While cannabidiol and other marijuana-derived substances are traditionally smoked, this can cause damage to the lungs, and edible cannabis products have their drawbacks, too—typically being filled with sugars or other sweeteners to mask the unpleasant flavor associated with cannabis compounds. With its pioneering TurboCBD™ product, however, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral CBD intake, having engineered the product to enhance absorption through the intestinal tract without active compounds being destroyed by stomach acid or broken down by the liver, and this revolutionary product also masks the unpleasant flavor of cannabis compounds. An article further discussing this…

Continue Reading

FridaySep 15, 2017 1:36 pm

CannabisNewsBreaks – Recent Competitor Recalls Illustrate Importance of ABcann Global’s (TSX.V: ABCN) (OTCQB: ABCCF) Innovative, Pesticide-Free Cannabis Growth Practices

Recently, the Canadian government announced that Broken Coast Cannabis Ltd. was recalling several products sold in 2016 due to the discovery of two banned pesticides in random samples, and several other Canadian cannabis growers have also had product recalls this year after banned pesticides were discovered in their products during mandatory testing. Instances like these serve to further illustrate the importance of the controlled, pesticide-free medical marijuana growth practices of ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), which continues to meet product demand through its Napanee, Ontario, production facility and is also moving forward with expansion plans. An article further…

Continue Reading

FridaySep 01, 2017 12:07 pm

CannabisNewsBreaks – InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) Could Prove to Be a Cannabis Biotech Unicorn

The recent solar eclipse that enthralled the world has come and gone, but no shadow of an eclipse is on the horizon to blot out the progress of InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). As peer valuations have soared in Canada’s cannabis market, InMed continues its promising R&D efforts into the therapeutic benefits of marijuana, and this Vancouver, Canada-based company may just prove to be one of the unicorns of Canada’s cannabis biotech market. An excerpt from an article further discussing this reads: “InMed Pharmaceuticals has more to offer than the typical drug discovery and development company. Its triple…

Continue Reading

FridayAug 25, 2017 12:00 pm

CannabisNewsBreaks – Disruptive Process Pioneered by Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Creates Superior Cannabis Edibles

Common complaints among consumers of cannabis edibles include the presence an unpleasant taste, but this and other inadequacies are being overcome through the innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria’s disruptive process masks the unpleasant taste of cannabis, and the company’s lipophilic enhancement technology also changes the way cannabinoids enter the body while significantly speeding up the timeframe in which THC’s effects are felt and increasing bio-absorption by as much as tenfold. As noted in a recent NNW article: “Because cannabinoids are absorbed poorly by the gastrointestinal tract, many cannabis users turn to other administration routes, like…

Continue Reading